ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Lenvatinib in combination with nivolumab demonstrated promising antitumor activity in patients with unresectable hepatocellular carcinoma with no new safety signals reported.
Feature:

Coverage from the 2020 ASCO Gastrointestinal Cancers Symposium Learn More >>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.